1. FDA isn’t any easier, but it is more stable.
For many years, especially in the late 2000s, it felt like high-risk innovations were not getting funded. There were many reasons for this. Of course, there was the recession, but also FDA was in flux. Corporations stopped buying companies, and FDA was revamping itself. Now, FDA has made itself very available to firms and the process is transparent. That isn’t to say going through the FDA process is any easier, but the stability has made investors more interested. At the same time, reimbursement has scaled. Proving economic value is equal to or even more important than satisfying FDA.